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Abstract (words 250) 
Background: 
A clinical and research challenge is to identify which depressed youth are at risk of “early 
transition to bipolar disorders (ET-BD)”. This two-part study (i) examines the clinical utility of 
previously reported BD at-risk (BAR) criteria in differentiating ET-BD cases from unipolar 
depression controls (UP); and (ii) estimates the Number Needed to Screen (NNS) for research 
and general psychiatry settings. 
 
Methods: 50 cases with reliably ascertained, early transition to BD I and II were matched for 
gender and birth year with 50 UP who did not develop BD during two years of prospective 
follow-up. We estimated the clinical utility for finding true cases and screening out non-cases 
for selected risk factors and their NNS. Then, using a convenience sample from routine practice 
(N=80), we estimated the NNS when adjustments were made to take into account missing data.  
 
Results: Five features (sub-threshold mania, cyclothymia, family history of BD, atypical 
depression symptoms and probable antidepressant-emergent elation), occurred significantly 
more frequently in ET-BD youth. Each of these ‘BAR-Depression’ criteria demonstrated clinical 
utility for screening out non-cases. Only cyclothymia demonstrated good utility for case finding 
in research settings; sub-threshold mania showed moderate utility. In the convenience sample, 
the NNS for each criterion ranged from ~4 to 7. 
 
Conclusions: Cyclothymia showed the optimum profile for case finding, screening and NNS in 
research settings. However, its presence or absence was only reported in 50% of clinical case 
notes. Future studies of ET-BD instruments should distinguish which criteria have clinical utility 
for case finding versus screening. 
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Introduction  
Globally, the peak age at onset (AAO) of severe mental disorders such as bipolar (BD) and 
psychotic disorders is late adolescence and early adulthood1-3. Since the turn of the century, 
researchers have begun to identify subgroups of help-seeking youth who are at ultra-high risk 
(UHR) of early transition from a late prodromal stage to a first episode of psychosis (FEP). The 
risk of transition varies between about 15% and 35% over 12-24 months, but it can be 
predicted by UHR criteria, namely the presence of a combination of a limited set of state, trait 
and familial characteristics4-5. Furthermore, these features can be incorporated into screening 
tools that can be applied in a range of settings. This enables the early identification of UHR 
individuals who can be monitored prospectively through a critical period of enhanced risk for 
the onset of FEP and offered clinical interventions if appropriate6. 
 
In keeping with the UHR concept in psychotic disorders, several tools to identify young people 
at increased risk of BD have been applied in research settings, specialist clinics and tertiary 
referral centres7-11. To date, the only instrument with published data on predictive validity in 
the peak AAO group is the BD at-risk (BAR) assessment tool7. The BAR has good reliability (free 
range kappa 0.83), and incorporates generic risk factors (e.g. being in the peak AAO range for 
BD onset) alongside a set of specific criteria, namely: cyclothymia co-occurring with depression, 
sub-threshold mania, and depression co-occurring with genetic risk (i.e. a family history of BD). 
A case note audit of 173 systematically assessed referrals to the ORYGEN early intervention 
services (in Melbourne, Australia) found that one in seven youth aged 15-24 years met criteria 
for at least one BAR subgroup (BAR+). In BAR+ cases, the transition rate to (hypo)mania was 
about 23% over an observation period of about 250 days compared with 0.7% in the BAR- 
controls7. In a further prospective study undertaken by the same research group (35 BAR+ 
cases matched with 35 BAR- controls), early transition to BD (14%) occurred in BAR+ cases 
only12. A sub-analysis (N=52) of this case-control study demonstrated that sub-threshold mania 
was the most significant predictor of early transition to BD in those youth with common mental 
disorders, such as depression and anxiety13. 
 
Identifying BAR or UHR-BD criteria is clinically important, but published studies on all the 
available instruments have been limited to the centres where the assessment tools originated. 
The generalizability of BAR criteria to other clinical settings and locations, and the clinical utility 
and discriminant validity of the proposed criteria warrants further examination in larger 
samples of early transition to BD (ET-BD) cases. Critically, it is important to determine whether 
the BAR criteria can distinguish which youth with early onset depression are at risk of ET-BD 
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(i.e. who show transition within about two years)5-6. Also, information is needed on how the 
BAR assessment tool might perform in day to day clinical practice, where the quality of case 
note recordings may be sub-optimal, and ratings of the presence or absence of specific signs and 
symptoms may be less reliable than in specialist or research settings that employ systematic 
assessments.  This two-part study aims to address the following:  
First, using a case-control methodology we examine the: 
a) Discriminant validity of the BAR criteria in differentiating ET-BD youth from unipolar 
depression controls (UP), who were matched for gender and year of birth  
b) Clinical utility of the original BAR criteria and of five additional clinical features for 
finding BD cases and for screening out non-cases  
c) Number Needed to Screen (NNS) using comprehensive, systematic assessments 
undertaken in research settings. 
Second, using a convenience sample we estimate:  
d) the NNS if screening of case notes is undertaken in routine clinical practice.  
 
Methods  
The Appendix provides further detailed descriptions of the sampling, rationale for selection of 
risk factors, additional information on statistics and other basic data. 
 
The methods for Part I and Part II of the study are briefly summarized below. 
 
Part I: Case-control study 
Sample- This sample comprised of 100 cases (50 ET-BD; 50 UP) who were identified from de-
identified data from systematic, comprehensive, clinical assessments that had previously been 
entered into eight databases designated appropriate for data sharing (in accordance with the 
recommendations of the Organisation for Economic Co-operation and Development14).  
 
The 50 ET-BD cases were selected if they met the following criteria: (a) there was reliable 
evidence that the first episode of DSM IV15 mania or hypomania occurred between 15-25 years 
and (b) that the first (hypo)manic episode occurred within two years of a major depressive 
episode. These ET-BD cases were frequency matched for gender and year of birth to individuals 
with a diagnosis of UP. The 50 UP controls also met the criteria of reliable evidence that they 
had experienced a major depressive episode that met DSM IV criteria between the ages of 15-25 
years. The key characteristics of the final sample are shown in Table 1. 
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Measures: Extended Bipolar at Risk (BAR) criteria - Bechdolf et al’s7 BAR criteria explore the 
presence or absence of four clinical characteristics prior to the onset of the first episode of 
(hypo)mania. These four variables are used to identify three at risk subgroups ([1] sub-
threshold mania; [2] depression and cyclothymic features; [3] depression and genetic risk of BD 
(family history of BD). These criteria were supplemented by assessment of the presence or 
absence of five other clinical features that may be risk factors for the onset of BD I or II (see 
Appendix for details): probable antidepressant-emergent elation; psychotic symptoms during a 
mood episode; psychomotor retardation; atypical depression (anergia and/or hypersomnia); 
and family history of (i) multiple generations (>=2) affected by mood disorders, or (ii) other 
mood or alcohol and substance misuse disorders (ASUD). 
 
Statistical Analysis- As described in the Appendix, we used several established approaches to 
examine the statistical significance and clinical utility of the selected risk factors in 
differentiating between cases with early transition to BD and UP controls. We focus on- 
 
a) Odds Ratio and 95% Confidence Intervals (95% CI) was calculated for each clinical 
characteristic.  
 
A review of original studies and meta-analyses of youth with mood disorders indicated that 
most of the clinical features being tested occurred in at least one in ten participants (except 
multi-generational family history, for which we could not identify a reliable prevalence 
rate).  Thus, assuming an overall sample prevalence of at least 10% for each variable, we 
estimated that the size of the sample gave 90% power at a 5% level to detect an OR >=1.98 
in the matched case-control analyses.  
 
b) Clinical Utility Index (CUI): Mitchell notes that when using a risk factor or symptom to find 
true cases or screen out non-cases, the real world clinical relevance of any item will be 
reduced if it arises infrequently16. As such, the Clinical Utility Index (CUI) is increasingly 
recommended as an alternative to sensitivity or positive predictive values etc. (data shown 
in the Appendix), as it reflects both the discriminatory ability of a factor or criteria and its 
overall occurrence in the population being examined17. The CUI+ (=Positive Predictive Value 
x Sensitivity) represents an estimate of the utility of a symptom or risk factor in case finding 
(the Rule In accuracy). The CUI- (= Negative Predictive Value x Specificity) reflects the utility 
for screening out non-cases (the Rule Out accuracy).  
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We calculated the CUI+ and CUI- for each feature selected and report the scores 
according to Mitchell’s17 grading of utility: poor (0-0.2), fair (0.21-0.39), moderate (0.4-
0.59), good (0.6-0.79), or excellent (> 0.8). If the CUI+ exceeds the CUI-, an item is 
regarded as better for case finding; if the CUI- exceeds the CUI+, the item is better for 
screening. We report the overall CUI for those factors where either the CUI+ or CUI-were 
graded as good. 
 
c) Number Needed to Screen (NNS):  similar to the Number Needed to Treat, the NNS 
represents the number of patients that need to be screened to yield one additional, 
correct identification of a case or non-case, beyond those who are misidentified18,19. The 
NNS were estimated for each BAR criterion with significant OR and 95% CIs (see 
Appendix for the formula). 
 
Part II: Convenience sample study 
Sample- With ethical approval, a convenience sample of 80 cases of DSM IV mood disorders (40 
individuals with UP and 40 with BD) attending general psychiatry outpatient clinics was 
identified20.  
 
Measures-The case notes were screened using an itemized checklist and the frequency with 
which key clinical information was recorded as present or as absent was noted (see Appendix 
for details). Data on the prevalence of missing information was extracted20. 
 
Statistical Analysis: NNS for routine clinical practice- the NNS for each BAR criterion with a good 
CUI+ or CUI- (in the case-control study) was re-calculated to take into account the rates of 
missing information in the clinical case notes. 
 
 
Results  
As shown in Table 1, the ET-BD cases and UP controls were more likely to be female (62%), 
with similar AAO for minor and major mood episodes. There were marginal group differences in 
number of prior mood episodes (BD>UP) or comorbidity rates (UP>BD). 
 
Table 1 about here 
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As shown in Table 2, the OR estimates demonstrate that the risk factors that best discriminated 
between ET-BD cases and UP controls were, in order of magnitude: sub-threshold mania (OR: 
16.9; 95% CI: 4.7, 61.8), cyclothymia (OR: 14.2; 95% CI: 5.4, 37.2), atypical depression (OR: 
11.5; 95% CI: 3.6, 36.7), family history of BD (OR: 7.6; 95% CI: 1.6, 35.9), and evidence of 
probable antidepressant-emergent elation (OR: 3.4; 95% CI: 1.2, 4.9).  
 
Table 2 about here 
 
The CUI scores showed that cyclothymia had a good CUI+ (0.62) and CUI- (0.62) grading for 
discriminating ET-BD cases from UP controls. Also, these gradings suggest that cyclothymia has 
clinical utility for both case finding and screening. Other items had better utility for screening. 
Sub-threshold mania had a moderate CUI+ (0.46) and a good CUI- (0.62) grading, whilst 
probable antidepressant-emergent elation demonstrated a fair CUI+ (0.22) but a good CUI- 
grading (0.66). Family history of BD had a relatively poor CUI+ grading (0.20), but a moderate 
CUI- grading (0.54). 
 
Table 3 about here 
 
Table 3 shows that the NNS estimates for the five selected BAR items. In systematically assessed 
cases the NNS ranged from 1.7 (for cyclothymia) through to 5.0 (for family history of BD). In the 
convenience sample, the predicted NNS ranged from 3.5 to 6.9. The NNS for family history 
showed the smallest difference between research and clinical settings (rising from 5.0 to 5.9), 
reflecting the fact that the presence or absence of this criterion was routinely recorded in 
clinical practice (84% of case notes). 
 
Discussion 
Increasing attention is being given to the identification of youth at risk of a first onset episode of 
BD21. Previous research on screening for BD suggested that self-rating instruments, e.g. the 
Mood Disorders Questionnaire22, may help to identify pre-existing, unrecognized cases of BD in 
older adults. However, they cannot be recommended for use as a screening instrument in 
individuals at risk of early transition from depression to BD23-25.  As such, the need to better 
identify ET-BD has led to the appearance of several new ‘BAR’ instruments that differ in terms 
of time for completion, complexity and comprehensiveness7-11. We chose to examine Bechdolf et 
al’s7 BAR assessment tool, which has the benefit of brevity, established reliability, and emerging 
evidence of predictive validity. The present study builds on the research on the BAR instrument 
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and its criteria in four important ways. First, we applied the criteria in a new clinical setting and 
used them for the first time outside of the location where the assessment tool was developed 
and tested. Second, we assessed a set of extended BAR criteria in a larger number of ET-BD 
cases than previously studied (the largest subgroup reported was 35 BAR+ cases)7,12,13. Third, 
we identified two additional features, antidepressant-emergent elation and atypical depression, 
that may enhance the utility of the BAR tool to identify ET-BD in cases of major depression aged 
15-25 years. Fourth, we use easily interpretable parameters for describing the performance of 
each criterion, as the CUI and NNS are easier to understand and potentially more relevant to the 
planning of screening or case finding than other measures such as odds ratios, sensitivity, 
specificity, or positive and negative predictive value16-19. 
 
This study found that the three original BAR items plus two additional variables (a set which we 
will refer to as BAR-Depression or BAR-D criteria) occurred significantly more often in ET-BD 
cases compared to UP controls, and that these trait, state and familial markers demonstrated 
moderate to good clinical utility for screening out non-cases. The NNS for each criterion was 
highly acceptable for research settings (about 2-5). Although the NNS for each criterion was 
slightly higher in routine clinical settings (range about 4-7) this finding seems to parallel the 
original case note audit by Bechdolf et al7 that revealed that one in seven youth met at least one 
BAR criterion. Overall, the BAR-D items show lower utility for case finding, and only 
cyclothymia and sub-threshold manic symptoms showed good or moderate capacity to 
differentiate ET-BD from UP. Although the current performance of sub-threshold mania was 
modest, it has previously been found to be a significant predictor of imminent transition to 
mania in a small scale study using BAR criteria in Australia13 and a large scale study of offspring 
of bipolar parents in the USA26.  
 
The current study suggests that cyclothymia has the optimum profile for case finding, screening 
and NNS. However, the apparent clinical utility of cyclothmia must be counterbalanced by two 
observations. First, whilst this temperamental feature can be reliably defined and assessed in 
the research datasets (e.g. using established personality assessment schedules), its presence or 
absence was not reported in half of the clinical case notes examined (in the convenience 
sample). Second, whilst systematic clinical assessments can usually discriminate between 
cyclothymia and sub-threshold manic symptoms (and other forms of affective instability), it is 
not clear whether these trait and state phenomena are dependably differentiated in routine 
clinical practice25,27. Third, these variables may co-occur at a rate that is greater than previously 
anticipated28. Taking all these issues into account, we suggest that an important implication of 
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the current study is that clinicians may need help to develop their skills in detecting cyclothymia 
as well as encouragement to routinely record its presence or absence in youth with depression. 
 
The findings on family history of BD are worthy of further discussion. Clinical and research 
evidence suggests that family history of BD is one of the most robust predictors of future onset 
BD29,30; and we found that clinicians recorded information about family history more than any 
other risk factor for BD. However, the present study confirms that the overall prevalence of a 
positive family history of BD in general psychiatry datasets is lower that reported in specialist 
clinics and research environments31. Furthermore, the recent National Institute of Healthcare 
and Clinical Excellence (NICE) guideline on BD suggests that the presence of family history of 
BD in cases of depression should not be used to identify potential risk of BD32 as it predicts both 
recurrent UP as well as BD33 and genetic loading for BD alone may not be sufficiently 
discriminatory33. Also, recent research suggests that other factors, e.g. AAO of BD in a parent, 
may play a role in heritability and the likelihood of early onset in offspring34. Given these data, 
our finding that family history of BD in depressed youth is better for screening than for case 
finding seems to be a conservative, but realistic proposition.  
 
Antidepressant emergent elation appeared to demonstrate sufficient clinical utility for use as a 
screening item. However, as noted in the Appendix, a significant problem arose in assessing the 
‘probable’ presence of elation that may be associated with antidepressant35. The definition we 
used could be applied with moderate confidence only to the data derived from systematic 
assessments, and it was clear from scrutiny of the general psychiatry case notes that clinicians 
apply idiosyncratic criteria or do not document how they have operationalized the term (and 
they often use the term antidepressant emergent elation inter-changeably with antidepressant-
emergent mood instability). As such, we suggest caution in regard to considering ‘probable’ 
anti-depressant emergent elation as a BAR criterion until there is greater consensus on how to 
define and assess it, including agreement about the maximum duration of the time delay 
between prescription of an antidepressant and the onset of these mood changes, and the level of 
severity and duration of mood and other symptoms required35. Having highlighted these 
concerns, it is noteworthy that the current edition of DSM (DSM-5) recognizes that (hypo)manic 
episodes that emerge during antidepressant treatment are indicative of underlying BD, and so 
we encourage more research on this phenomenon in depressed youth.  
 
Recommending the use of atypical depressive symptoms for screening is less problematic, as 
increases or decreases in sleep, appetite, activity and energy, are key criteria for the diagnosis of 
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depressive episodes. Unsurprisingly, the presence or absence of these features was recorded in 
more than 70% of case notes. Indeed, it is unclear why these features are not employed in 
screening more often as many, but not all, studies indicate their potential importance in 
differentiating BD from UP36-38. 
 
The study has several limitations, most notably that none of the datasets we accessed was 
derived from studies designed for the purposes of assessing risk of ET-BD in the peak AAO 
period (15-25 years). The age range was selected because it represents the peak AAO for BD, 
but it can be argued that these boundaries were somewhat arbitrary. Also, the 24-month time 
frame for transition from depression to BD can be viewed in the same light. However, we would 
argue that it represents a pragmatic decision based on research evidence and clinical relevance. 
First, research on UHR criteria for psychosis and related evidence regarding time to transition 
suggests that two years is a critical time period39 and that rates of transition then start to fall. 
Second, we suggest that it would be feasible and justifiable to monitor depressed youth at risk of 
ET-BD for this time period to offer the prospect of early interventions as appropriate40.   
 
Instead of using a prospective cohort study approach, we chose a case-control methodology. 
The rationale for the sampling strategy was that we wanted to ascertain a large number of ET-
BD cases to maximize the statistical power of the clinical utility and NNS analyses. However, a 
weakness of this approach is that it assumes a degree of homogeneity in the clinical populations 
recruited into the original datasets we accessed and that the prevalence rates for the BAR risk 
factors in the case-control sample reflect the true prevalence in other clinical and community 
settings. Although the base rates for each criterion were within the predicted ranges, they were 
slightly lower than anticipated for some features (e.g. psychotic symptoms and psychomotor 
retardation). This reduced the power to detect significant OR and may mean we have 
prematurely excluded some variables from the NNS analyses. The use of a convenience sample 
can also be criticised as a potential source of biases, although we emphasize that the data were 
only used in the prediction of the NNS in routine clinical practice. This calculation, by definition, 
required access to clinically representative, general psychiatry case records. Lastly, we decided 
that the recruitment procedure for the case-control study, the sample size and the nature of the 
available data meant it was inappropriate to explore any additive effects for combinations of 
risk factors, or to undertake survival analyses of time to transition associated with each risk 
factor. However, it is important to note that the largest NNS is the rate limiting step for 
screening (so effects on speed of transition or additive effects) does not change the workload for 
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screening or case finding. These important issues are being addressed in a larger-scale 
prospective cohort study.   
 
In conclusion, this study is the first we know of that examines the clinical utility and 
discriminant validity of each factor included in Bechdolf et al’s BAR criteria7 and of other 
selected trait, state and familial markers of risk of ET-BD in depressed youth. Cyclothymia in 
individuals with depression showed the optimum clinical utility as it is useful for both case 
finding and screening, and showed the lowest NNS. Unsurprisingly, sub-threshold mania also 
showed utility. Other clinical features (family history of BD, probable antidepressant emergent 
elation and atypical depression) had better utility for screening out non-cases than for case 
finding.  
 
We suggest that future prospective studies of BAR tools should report the clinical utility for 
screening and case finding of each criterion they include, alongside their NNS. In this way it will 
be possible to compare these different key aspects across studies and also to determine if some 
tools are more applicable to selected populations (e.g. specialist mood clinics, early intervention 
in psychosis services, etc.).  For example, the BAR-D tool may be more useful for screening 
young people with major depression who are in the peak age range for risk of ET-BD than for 
other populations.  
 
Lastly, we draw attention to the widely held view that youth mental health research would 
benefit from a trans-diagnostic approach. This is particularly relevant in determining the 
longer-term trajectories of severe mental disorders, many of which demonstrate at least one 
episode of depression during the earliest clinical stages4-6,12,35. As such, it is of considerable 
interest that there appears to be convergence in the type of criteria being employed in psychosis 
and BD to define risk syndromes (combinations of limited sets of state, trait and familial 
characteristics)4,5,7. State characteristics  examined in the BAR criteria, such as brief, attenuated 
of sub-syndromal manic symptoms, clearly parallel the descriptor used in psychosis4. There are 
also similarities in the risk rates for transition to psychosis4,5 and to BD7,12.  This would seem to 
indicate that it may be possible to develop a combined tool that could not only further our 
understanding not only of who is at risk of ET-BD, but also identify if any characteristics are 
unique to a ‘mood disorder trajectory’ and which may be shared with individuals who make a 
transition to psychosis. Clinically, this may help to plan generic as well as specific interventions 
and treatments 40. It would also provide opportunities for research into underlying 
pathophysiological mechanisms associated with transition6,35,37. 
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Table 1: Characteristics of cases with early transition to bipolar disorder (ET-BD) and controls with  
unipolar disorder (UP) who were matched for gender and year of birth 
 
 
 
Clinical Characteristicsa ET-BD (N=50) UP (N=50) 
Number of Females 31 31 
Median Age (IQ range) in years-   
1st Episode Minor Depression 13.3 (8-16) 13.5 (8-16) 
1st Episode Major Depression 17.0 (15-20) 18.0 (16-22) 
1st Episode Hypomania or Mania 20.3 (17- 23)  
Median Number of Mood Episodes (IQR)b 4 (2-6) 3 (2-5) 
Number with a Comorbid Mental Disorder or ASUD 7 8 
 
ET-BD: Early Transition to Bipolar Disorder; UP: Unipolar Disorder; ASUD: Alcohol or Substance Use 
Disorder.  
aMedian and inter-quartile range (IQR) are reported as the age range of the sample is truncated, or the 
characteristic was not normally distributed. 
bAssessment of number of episodes is truncated to age=<25 years (see text for details). 
 
   
Table 2: Prevalence and performance of each putative risk factors for bipolarity in differentiating between cases with early transition to bipolar (ET-BD)  
and controls with unipolar disorders (UP). 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
aCriteria from Bechdolf et al (2010); bFactors identified from research literature (see Appendix 1 for details) 
ET-BD: Early Transition to Bipolar Disorder; UP: Unipolar Disorder; ASUD: Alcohol or Substance Use Disorder. 
CUI= Clinical Utility Index (see text for details and numerical estimate of grading). 
 cOverall clinical utility is only reported if the item received a good grading for either the CUI+ or CUI-.  
 
 
ET-BD 
(N=50) 
UP 
(N=50) 
Odds 
Ratio 
(95% CI) 
Clinical 
Rule In 
Accuracy 
(CUI+) 
Clinical 
Rule Out 
Accuracy 
(CUI-) 
Overall  
Clinical Utilityc 
Bipolar at Risk Criteriaa       
Cyclothymia  39 10 
14.2 
(5.4, 37.2) 
good good 
Case Finding & Screening 
Sub-threshold Mania 26 3 
16.9 
(4.7, 61.8) 
moderate good 
Screening 
Family History of BD  12 2 
7.6 
(1.6, 35.9) 
poor good 
Screening 
Additional Risk Factorsb       
Probable Antidepressant-
emergent Elation  
21 8 
3.4 
(1.2, 4.9) 
fair good 
Screening 
Atypical Depression 25 4 
11.5 
(3.6, 36.7) 
fair good 
Screening 
Psychomotor Retardation 6 2 
2.6 
(0.5, 13.6) 
poor moderate 
- 
Psychotic Mood Episode 6 1 
6.7 
(0.8, 57.7) 
poor moderate 
- 
Family History of other Mood 
Disorders &/or ASUD 
22 14 
2.0 
(0.9, 4.64) 
fair moderate 
- 
Multi-generational Family 
History of Mood Disorders 
3 0 
3.1 
(0.3, 31.1) 
poor moderate 
- 
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Table 3:  Estimated Number Needed to Screen (NNS) for selected clinical features of early transition from  
  depression to bipolar disorders for individuals assessed by structured systematic clinical  
 interview schedules and the predicted NNS in routine clinical settings. 
 
 
 
 
Clinical Features 
Overall  
Clinical 
Utility 
NNS with 
Systematic 
Assessmen
t 
Proportion 
of Case 
Notes with 
Missing 
Dataa  
Predicted 
NNS in 
Routine 
Clinical 
Practice 
Cyclothymia  
Case 
Finding & 
Screening 
1.7 51% 3.5 
Sub-threshold Mania Screening 2.2 68% 6.9 
Probable Antidepressant-emergent Elation  Screening 2.8 39% 4.6 
Atypical Depression  Screening 4.5 27% 6.2 
Family History of Bipolar Disorder  Screening 5.0 16% 5.9 
      
NNS: Number Needed to Screen 
a The percentage refers to the proportion of clinical case notes that failed to report either the presence or 
absence of the clinical feature. 
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Appendix: Further Details on Methodology 
 
Samples  
Sample 1- Systematically assessed cases: The sample (n=100) was derived from eight datasets1-8 that were 
selected on the basis that the study samples were recruited from general psychiatry settings and some or 
all of each sample was comprised of cases of bipolar (BD) or unipolar disorders (UP). The databases were 
chosen as they recorded information from structured, systematic, undertaken by trained clinical 
researchers that used reliable and valid assessments of current and lifetime DSM IV diagnoses, 
personality and temperament, comorbid disorders, family history, etc. (for example, the Structured 
Clinical Interview for DSM IV; the Family Interview for Genetics Studies; Personality Assessment 
Schedule; the WHO treatment equivalence ratings of medications, etc.). In  addition, many of studies that 
incorporated repeated face to face interviews established inter-rater reliabilities for ratings made by the 
researchers (e.g. Medical Research Council funded study of cognitive therapy for BD1).Further details of 
the ethical procedures, recruitment processes, and specific clinical assessments and schedules and 
baseline and follow-up procedures are given elsewhere2-8 (including a publication that refers to Alison 
Jackson’s PhD at University of Glasgow from which some data was extracted8).  
 
The datasets included 691 UP and BD cases where the ratings that were recorded in the dataset allowed 
the age at onset (AAO) of a first depressive and/or a first (hypo)manic episode to be ascertained. In 
addition, in BD cases, it was possible to estimate the time between a depressive episode and the first 
(hypo)manic episode, and the systematic assessments of individuals with UP and BD used assessment 
tools that recorded information that could be used to rate the presence or absence of each of the BAR 
criteria when using the assessment tool9 and of the additional items selected (see next section) that we 
chose to examine. For example, the use of the Family Interview for Genetics Studies allowed the BAR 
criteria on genetic risk and other specified details of family history to be identified. It is important to 
highlight that, in some datasets, the individual participating in the assessment was older than 25 years, 
but the data reported the AAO and sufficient details on episode polarity, timing and frequency to allow 
the case to be considered for inclusion in the study sample. This approach is frequently used in long-term 
cohort studies that use intermittent follow-ups every 2-3 years (e.g. Dunedin study). The approach is 
referred to as ambi-perspective (i.e. meaning that it is possible to date illness episodes and build a 
longitudinal picture of events that precede or follow the episode onset). 
 
Using this approach, we identified 50 BD cases (BD I or II) with reliable evidence that their first episode of 
DSM IV10 mania or hypomania occurred (i) between 15-25 years and (ii) no more than two years after a 
major depressive episode. Frequency matching was used to match these BD cases for gender and year of 
birth to individuals with recurrent UP who met DSM IV10 criteria for their first major depressive episode 
(i) between 15-25 years, (ii) did not demonstrate transition to BD during two years of prospective follow-
up or by the age of 25 years. We matched cases for birth year rather than age of first episode of any mood 
or non-affective psychopathology as research suggests that these might be expected to differ between UP 
and BD e.g. BD may have earlier AAO of depression compared to UP11,12, and to avoid confounding from 
any putative birth cohort effects13.  
 
Sample 2- Clinically assessed cases: Ethical approval was obtained from Newcastle Joint University and 
Hospital Ethics committee to review the case records of a convenience sample of 40 individuals with UP 
and 40 with BD attending general psychiatry outpatient clinics. The project was independent of the 
present study and all the consultant psychiatrists who identified the cases for inclusion in the project and 
the researchers were blind to the aims of the present study14.  
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The case notes were screened to determine the frequency with which the presence or absence of about 
40 putative risk factors for BD that were described on a checklist14. The recordings did not need to 
demonstrate the reliability or validity of the assessment, but needed to use a term that allowed the report 
to be classified into one of the categories. A small number of categories were collapsed into one item as 
they were often used interchangeably e.g. probable antidepressant emergent elation and antidepressant 
emergent mood swings were often combined into one category. In other circumstances (e.g. if a case note 
recording was difficult to interpret), information was allocated to the most appropriate category by 
consensus between researchers (Ivatt, Scott, or Professor Ferrier or Dr Meyer).  
 
 A frequency table was created that recorded the proportion of case notes that had recorded information 
about each factor (details available from the first author). From this list it was possible to calculate the 
percentage of case notes with missing data regarding each variable that was of interest in the current 
study.   
 
Measures: Extended BAR Criteria 
Time period for ratings: In this study, we assessed the prevalence of the extended BAR criteria in Sample1. 
In the ET-BD cases, we noted the occurrence prior to the onset of the first episode of (hypo)mania; in the 
UP controls, we noted the occurrence prior to the age of 25 years (or the end of the follow-up period if 
that was sooner). 
 
Bipolar At Risk (BAR) criteria- Bechdolf et al’s9 BAR criteria use a combination of four clinical 
characteristics to identify three ‘at risk’ subgroups ([1] sub-threshold mania; [2] depression and 
cyclothymic features; [3] depression and genetic risk of BD). An individual is regarded as BAR+ if the 
researcher reliably demonstrates that the presence of any of the state or trait features preceded the onset 
of the first (hypo)manic episode that met recognized diagnostic criteria (such as DSM IV). If the timing 
was unclear and no other data were available, the criterion was rated as absent. 
 
The BAR assessment incorporates five exclusion criteria (IQ below normal range; evidence of organic 
brain disorder; past history of a treated or untreated manic episode; prior treatment with a mood 
stabilizer; presence of psychotic symptoms); we applied these to our sample selection, with the exception 
of the presence of psychotic symptoms. We included psychotic symptoms in our study as there is 
evidence to suggest that these can discriminate between youth at risk of BD compared with recurrent 
UP15 and they have been found to predict transition to BD in a meta-analysis of studies of depression16. 
Also, if we wish to screen for ET-BD in early intervention (for psychosis) services, it will be clinically 
important to explore whether the presence or absence of psychotic symptoms affects the performance of 
the BAR criteria. 
 
Additional Risk Factors- 
Five additional putative risk factors were included in this study as it was hypothesized that these might 
enhance the ability of the BAR criteria to identify which depressed youth were at risk of early transition 
to BD (ET-BD). The items were included on the basis that there was robust evidence to suggest they are 
risk factors for early onset mood disorders and/or may be useful in differentiating BD and UP16-25. 
Furthermore, one factor (probable evidence of anti-depressant emergent elation), was selected as all the 
transitions to BD showed evidence of this feature in the original study by Bechdolf et al9. (However, we 
would draw attention to the fact that in Sample 2, some clinicians making case note recordings had 
combined this item and recorded it as ‘probable evidence of anti-depressant emergent elation/mood 
stability’, which may affect the reliability or validity of any findings relating to the convenience sample).  
 The additional risk factors were- 
- Psychomotor retardation 
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- Evidence of psychotic symptoms during one or more mood episodes 
- Atypical depression (operationalized by two key features: fatigue and/or hypersomnia) 
- Family history of (a) multiple generations (>=2) affected by mood disorders or (b) other mood and 
alcohol and substance use disorders (ASUD). 
- Probable antidepressant emergent elation: to meet this criteria, we used similar definitions to those 
proposed in other studies of anti-depressant emergent mania (for a discussion see Brichant Petit-
John et al26), but adapted them for the purposes of this study. Namely, we regarded an individual as 
meeting this criterion if the mood elation or instability (i) occurred within 90 days of commencing 
treatment with a recognized antidepressant and (ii) was accompanied by at least one other symptom 
of mania. However, it is important to note, that this criterion was difficult to assess in some 
circumstances, and often required access to additional data records (e.g. such as free text). Given 
these uncertainties (and to be compatible with information recorded for Sample 2), we have reported 
the item as probable antidepressant emergent elation, but draw attention to the fact that the 
reliability of the assessment of this criterion was the lowest of any variable studied.  
 
Statistical Analysis 
We used several established approaches to examine the statistical significance and clinical utility of the 
selected factors in differentiating between ET-BD (cases) and UP (controls). However, whilst we 
calculated the sensitivity (Se) and specificity (Sp), and positive and negative predictive values (PPV; NPV) 
for each item, we do not report these in the main text as these were used purely to calculate the Clinical 
Utility Index (CUI)27,28. The calculations were as follows: CUI+ =PPVxSe, the CUI- = NPVxSp. (Data for the 
calculations is shown in the Table below). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The Number Needed to Screen (NNS) is analogous to the number needed to treat (NNT) in clinical 
treatment trials29-31. To estimate the NNS, it is first necessary to calculate the ‘fraction correct’ (i.e. the 
proportion of individuals correctly identified as cases or non-cases) and the ‘fraction incorrect’ (i.e. the 
error rate or proportion of misidentifications)30. The NNS is then calculated by the equation:  
NNS= 1/ [Fraction Correct -Fraction Incorrect]. 
 
We estimated the NNS for the factors most likely to differentiate between UP and ET-BD when structured 
systematic assessments are used (using OR findings from Sample 1). The predicted NNS for clinical 
settings was estimated using the formula: NNS using structured assessments/ proportion of case notes 
with missing information recording data on the item.   
  
 
ET-BD 
(N=50) 
UP 
(N=50) 
Se Sp PPV NPV 
Cyclothymia  39 10 .78 .80 .80 .78 
Sub-threshold Mania 26 3 .52 .94 .89 .66 
Family History of BD  12 2 .24 .96 .86 .56 
Probable Antidepressant-
emergent Elation  
21 8 .42 .84 .52 .78 
Atypical Depression 25 4 .50 .92 .72 .82 
Psychomotor Retardation 6 2 .12 .96 .75 .52 
Psychotic Mood Episode 6 1 .12 .98 .86 .53 
Family History of other Mood 
Disorders &/or ASUD 
22 14 .44 .72 .61 .56 
Multi-generational Family 
History of Mood Disorders 
3 0 .06 .99 .86 .51 
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